MedTrace Logo

Metformin in Patients With Ulcerative Colitis Treated With Mesalamine

NCT05553704 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-04-08

No results posted yet for this study

Summary

Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa, however, the exact underlying mechanisms of UC remain poorly understood.UC is strongly dependent on cellular immune reaction and exaggerated inflammatory response due to genetic, immune and environmental factors.

Conditions

  • Inflammatory Bowel Diseases

Interventions

DRUG

Metformin

metformin group will take mesalamine 1 gm three times daily plus metformin 500 mg two times daily

Sponsors & Collaborators

  • Mounir Hussein Bahgat Internal Medicine Department Mansoura University

    collaborator UNKNOWN

  • Maha Mohamed Maher Internal Medicine Department Mansoura University

    collaborator UNKNOWN

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2025-03-01
Completion
2025-03-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05553704 on ClinicalTrials.gov